SAN
JOSE, Calif., Oct. 28,
2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced a
presentation of additional data from the Phase 1 clinical trial of
its breast cancer vaccine at the Society for Immunotherapy of
Cancer (SITC) 39th Annual Meeting, being held virtually and in
Houston, Texas, from November 6-10, 2024. The trial is being conducted
in collaboration with Cleveland Clinic with funding by a grant from
the U.S. Department of Defense. The presentation, titled "Phase I
Trial of alpha-lactalbumin vaccine in high risk operable triple
negative breast cancer (TNBC) and patients at high genetic risk for
TNBC," will be presented by Dr. Emily
Rhoades, FDA/IND Trial Program Manager at Cleveland
Clinic.
Details of the poster presentation can be found below:
Poster Title: Phase I Trial of alpha-lactalbumin
vaccine in high risk operable triple negative breast cancer (TNBC)
and patients at high genetic risk for TNBC
Abstract #: 631
Date/Time: November 8, 2024, 12:15 p.m. CT
After the data is presented, Anixa will make the poster
presentation available on its website and through a public
announcement.
About Anixa Bioscience's Breast Cancer Vaccine
Anixa's breast cancer vaccine takes advantage of endogenously
produced proteins that have a function at certain times in life,
but then become "retired" and disappear from the body. One such
protein is a breast-specific lactation protein, α-lactalbumin,
which is no longer found post-lactation in normal, aging tissues,
but is present in certain breast cancers. Activating the immune
system against this "retired" protein provides preemptive immune
protection against emerging breast tumors that express
α-lactalbumin. The vaccine also contains an adjuvant that activates
an innate immune response, which allows the immune system to mount
a response against emerging tumors to prevent them from
growing.
Initial Phase 1 data was presented at the San Antonio Breast
Cancer Symposium in December 2023.
The data showed no safety concerns, with protocol defined immune
responses observed in a majority of patients.
The Phase 1 trial is conducted in collaboration with Cleveland
Clinic and is funded by a grant from the U.S. Department of
Defense. Anixa is the exclusive worldwide licensee of the novel
breast cancer vaccine technology developed at Cleveland Clinic. The
grant funding from the U.S. Department of Defense was provided to
Cleveland Clinic.
This vaccine technology was invented by the late Dr.
Vincent Tuohy, who was the Mort and
Iris November Distinguished Chair in Innovative Breast Cancer
Research in the Department of Inflammation and Immunity at
Cleveland Clinic's Lerner Research Institute. Cleveland Clinic
exclusively licensed this technology to Anixa Biosciences. The
Cleveland Clinic is entitled to royalties and other
commercialization revenues from the Company.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the
treatment and prevention of cancer. Anixa's therapeutic portfolio
consists of an ovarian cancer immunotherapy program being developed
in collaboration with Moffitt Cancer Center, which uses a novel
type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to treat and
prevent breast cancer and ovarian cancer, as well as additional
cancer vaccines to address many intractable cancers, including high
incidence malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-to-present-additional-data-from-phase-1-study-of-breast-cancer-vaccine-at-the-39th-society-for-immunotherapy-of-cancer-sitc-annual-meeting-302288176.html
SOURCE Anixa Biosciences, Inc.